Back to Trials
NCT05018663Recruiting

Artificial Intelligence (AI) Cytopathology Trial

The University of Texas Health Science Center, Houston

Start Date

7/21/2021

Completion Date

1/30/2028

Summary

Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs using standard of care. Sample slides are prepared by a cytopathologist at bedside and observed under a microscope. At the same time, the slides are scanned using a slide scanner and those images are saved for interpretation by AI at a later time.

Eligibility Criteria

Age Range: 18 years to 100 years

Inclusion Criteria: * Have EUS finding of a PSL; * Do not have contraindications for FNA/FNB. Exclusion Criteria: * Inability to provide informed consent for the procedure; * Contraindication for FNA/FNB eg coagulopathy, lack of avascular window for FNA.

Interventions

OTHER

Artificial Intelligence software ROSE

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Pancreatic Solid Lesions

Locations

Memorial Hermann Hospital

Houston, Texas 77030

United States